APP and early-onset autosomal dominant Alzheimer disease: It was also demonstrated that treatment with liraglutide was able to mitigate mitochondrial fragmentation by increasing the levels of Mfn-2 and OPA-1 and at the same time intensify the phosphorylation of DRP-1, thus promoting mitochondrial fusion over fission, which prevented hippocampal neuronal loss in a transgenic 5 × FAD mouse model of Alzheimer’s disease (expressing human APP and PSEN1 transgenes) [64].